TScan Therapeutics, Inc. (TCRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TScan Therapeutics, Inc., a Delaware corporation, on April 2, 2026. The report covers events occurring on March 31, 2026, regarding changes in the Company's principal accounting officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Resignation: Leiden Dworak resigned as Vice President of Finance and principal accounting officer, effective April 10, 2026.
- Appointment: Jason A. Amello, the Company's Chief Financial Officer, was appointed as the new principal accounting officer, effective April 10, 2026.
- Reason for Departure: The Company stated there were no disagreements with Mr. Dworak regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks. It notes that Mr. Amello will not receive additional compensation for the new role and that no changes were made to his existing plans or arrangements. Background information on Mr. Amello is incorporated by reference from the Company's Schedule 14A filed on May 14, 2025.
Key Facts for Investor Verification
- Confirm the effective date of the leadership transition (April 10, 2026).
- Review the definitive proxy statement (Schedule 14A) filed on May 14, 2025, for details on Jason A. Amello's background and contracts.
- Verify that no undisclosed disagreements or financial irregularities prompted the resignation of the former principal accounting officer.